Summary
Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is in cancer, cardiovascular, immunoscience and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic classes. The company offers its products across the world primarily to retail pharmacies, wholesalers, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, Japan and other countries. The company’s research activities focus on the discovery and development of novel medicines that address serious disease in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
Bristol-Myers Squibb Company (BMY) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Bristol-Myers Squibb Company, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Bristol-Myers Squibb Company, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Bristol-Myers Squibb Company, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Bristol-Myers Squibb Company, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Bristol-Myers Squibb Company, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Bristol-Myers Squibb Company, Medical Equipment, Deal Details 12
Venture Financing 12
Grail Raises USD914 Million in First Tranche of Series B Financing 12
Partnerships 14
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 14
HTG Molecular Diagnostics Enters into Research Agreement with Bristol-Myers Squibb 15
SomaLogic Enters into Agreement with Bristol-Myers Squibb 15
Leica Biosystems Enters into Co-Development Agreement with Bristol-Myers Squibb 16
InCell Enters Into Co-Development Agreement With Bristol-Myers Squibb 17
Adaptive Biotech Enters Into Co-Development Agreement With Bristol-Myers Squibb 18
Opko Health Expands Co-Development Agreement With Bristol-Myers Squibb For Alzheimer's Biomarkers 18
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 19
Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 20
Bristol-Myers Squibb Enters Into Co-Development Agreement With Meso Scale 21
Dako Enters Into Co-Development Agreement With Bristol-Myers 21
Bristol-Myers Squibb, Saladax Biomedical And Ortho-Clinical Diagnostics Expand Co-Development Agreement 22
Opko Health Enters Into An Agreement With Bristol-Myers Squibb 23
Equity Offering 24
GeneCentric Diagnostics Raises Funds through Equity Financing 24
Panmira Pharmaceuticals Spin Out from Amira Pharmaceuticals 25
Debt Offering 25
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 25
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 27
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 29
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 30
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 32
Acquisition 33
Bristol-Myers Rumored To Acquire Biogen Idec 33
Bristol-Myers Squibb Company - Key Competitors 35
Key Employees 36
Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 45
Strategy And Business Planning 45
Dec 13, 2016: Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint 45
May 17, 2016: Bristol-Myers Squibb Opens Expanded Biologics Facility 46
Mar 16, 2016: Allied-Bristol Life Sciences Launches ißeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway 47
Financial Announcements 48
Apr 27, 2017: Bristol-Myers Squibb Reports First Quarter Financial Results 48
Jan 26, 2017: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results 51
Oct 27, 2016: Bristol-Myers Squibb Reports Third Quarter Financial Results 54
Jul 28, 2016: Bristol-Myers Squibb Reports Second Quarter Financial Results 58
Jan 28, 2016: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results 61
Corporate Communications 64
Apr 10, 2017: Bristol-Myers Squibb Earns ENERGY STAR Partner of the Year Award for Third Consecutive Year 64
Mar 08, 2017: Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer 65
Feb 21, 2017: Bristol-Myers Squibb Appoints Three New Independent Directors 66
Dec 21, 2016: Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors 67
Jul 25, 2016: Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head 68
Jun 20, 2016: Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer 69
Mar 03, 2016: Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors 70
Feb 03, 2016: Bonnie J. Addario Lung Cancer Foundation Honors Bristol-Myers Squibb for Improving and Advancing Breakthrough Treatments for Lung Cancer 71
Product News 72
Sep 28, 2016: Intensity Modulated Radiation Therapy Associated with Reduction in Patient Reported Xerostomia in Head and Neck Cancer Patients 72
Jun 07, 2016: NRG RTOG 0617 Shows Survival Correlation for Low versus High Enrolling Institutions for Patients with LA-NSCLC 74
May 05, 2016: Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released 75
Apr 14, 2016: Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies 76
Other Significant Developments 77
Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre 77
Jun 01, 2016: Bristol-Myers Squibb Executive to Discuss New Data-Driven Approach to Driving Sales Excellence at 2016 LTEN Conference 78
May 19, 2016: Inovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based Contracting Initiatives 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80
List of Tables
Bristol-Myers Squibb Company, Medical Equipment, Key Facts, 2016 1
Bristol-Myers Squibb Company, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Bristol-Myers Squibb Company, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Bristol-Myers Squibb Company, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Bristol-Myers Squibb Company, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Bristol-Myers Squibb Company, Deals By Market, 2011 to YTD 2017 9
Bristol-Myers Squibb Company, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Grail Raises USD914 Million in First Tranche of Series B Financing 12
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 14
HTG Molecular Diagnostics Enters into Research Agreement with Bristol-Myers Squibb 15
SomaLogic Enters into Agreement with Bristol-Myers Squibb 15
Leica Biosystems Enters into Co-Development Agreement with Bristol-Myers Squibb 16
InCell Enters Into Co-Development Agreement With Bristol-Myers Squibb 17
Adaptive Biotech Enters Into Co-Development Agreement With Bristol-Myers Squibb 18
Opko Health Expands Co-Development Agreement With Bristol-Myers Squibb For Alzheimer's Biomarkers 18
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 19
Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 20
Bristol-Myers Squibb Enters Into Co-Development Agreement With Meso Scale 21
Dako Enters Into Co-Development Agreement With Bristol-Myers 21
Bristol-Myers Squibb, Saladax Biomedical And Ortho-Clinical Diagnostics Expand Co-Development Agreement 22
Opko Health Enters Into An Agreement With Bristol-Myers Squibb 23
GeneCentric Diagnostics Raises Funds through Equity Financing 24
Panmira Pharmaceuticals Spin Out from Amira Pharmaceuticals 25
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 25
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 27
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 29
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 30
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 32
Bristol-Myers Rumored To Acquire Biogen Idec 33
Bristol-Myers Squibb Company, Key Competitors 35
Bristol-Myers Squibb Company, Key Employees 36
Bristol-Myers Squibb Company, Subsidiaries 38
